

**INVESTOR WEBINAR NOTIFICATION**

**Genetic Signatures Limited (ASX: GSS)** (“GSS” or “the Company”), a global molecular diagnostics company, will host a live investor webinar at 10:00am (AEST) on Wednesday, 10 June 2026.

During the webinar the Company’s Chief Executive Officer, Maria Halasz, will provide an update on the findings of a 90-day review of the Company's operations, market position, product strategy and organisational structure. The following key areas will be addressed:

- **Cost reduction and updated capital management controls:** Annual savings of \$5M have already been implemented by reducing fixed and operational costs. Our aim is to continue to identify and implement cost management processes and rationalise product and instrument development programs which may result in further operational savings.
- **Market access strategy reset:** An overview of the global infectious disease diagnostic market has identified untapped opportunities in the UK, Europe and Asia Pacific. Current spending on US market access will be reallocated to these regions. Strengthening relationships with existing customers remains a key priority.
- **Product and instrument development strategy reset:** A product upgrade program will be implemented driven by market access and global regulatory requirements. The Optimus Prime instrument development project has been paused, and the Company’s existing instrument pool will be utilised for UK and regional launches in the medium term.

Further details will be outlined by the CEO during the investor webinar at 10:00am (AEST) on 10 June 2026. Participants will have the opportunity to submit questions during the session. To register for the webinar please visit the link below:

[https://vistra.zoom.us/webinar/register/WN\\_8bUMrhZLTwSXsAp5nLi1mw](https://vistra.zoom.us/webinar/register/WN_8bUMrhZLTwSXsAp5nLi1mw)

– END –

**Announcement authorised for release by the Board of Genetic Signatures Limited.**

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us:

**Maria Halasz**  
**Chief Executive Officer**  
[investors@geneticsignatures.com](mailto:investors@geneticsignatures.com)  
+61 2 9870 7580

**About Genetic Signatures Limited:**

Genetic Signatures is a molecular diagnostics company, specialising in detecting infectious diseases, using its patented **3base®** technology to simplify the genetic complexity of pathogen identification. The Company's automated diagnostic workflows accurately screen for multiple infectious pathogens with similar symptoms in a single test. Genetic Signatures' unique solutions enable laboratories to enhance diagnostic workflow and efficiencies, while reducing costs. Rapid results support infection control, appropriate patient management and disease surveillance, improving healthcare outcomes. Genetic Signatures continues to expand its global presence with direct representation in Australia, the United States and Europe, alongside international distribution partnerships.